"Direct targeting of STAT3 to reverse fibrosis"

Uddalak Bharadwaj, Ph.D.
Assistant Professor
Infectious Diseases
MD Anderson Cancer Center

Be informed about a highly-potent, non-toxic, direct STAT3 inhibitor, TTI-101, with excellent bio-availability, currently in a Phase I clinical trial (7 different cancers, including HCC, https://clinicaltrials.gov/ct2/show/NCT03195699. Know about its inhibitory effect on inflammation and fibrosis, especially, as it pertains to Hepatocellular Carcinoma


SEPT 17 • 4:00 PM

REGISTER AT HTTPS://EVENT.WEBINARJAM.COM/CHANNEL/DDCRESEARCHFORUM